LILRA1

Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 is a protein that in humans is encoded by the LILRA1 gene.[3]

LILRA1
Identifiers
Aliases	LILRA1, CD85I, LIR-6, LIR6, leukocyte immunoglobulin like receptor A1
External IDs	OMIM: 604810 HomoloGene: 134026 GeneCards: LILRA1
Gene location (Human) Chr. Chromosome 19 (human)[1] Band 19q13.42 Start 54,593,582 bp[1] End 54,602,381 bp[1]
Gene ontology Molecular function • antigen binding • transmembrane signaling receptor activity Cellular component • integral component of membrane • cell membrane • membrane Biological process • defense response • cell surface receptor signaling pathway • adaptive immune response • regulation of immune response • immune system process Sources:Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	11024	n/a
Ensembl	ENSG00000275525 ENSG00000277398 ENSG00000104974 ENSG00000274935	n/a
UniProt	O75019	n/a
RefSeq (mRNA)	NM_001278318 NM_001278319 NM_006863	n/a
RefSeq (protein)	NP_001265247 NP_001265248 NP_006854	n/a
Location (UCSC)	Chr 19: 54.59 – 54.6 Mb	n/a
PubMed search	[2]	n/a
Wikidata
View/Edit Human

References

1. ENSG00000277398, ENSG00000104974, ENSG00000274935 GRCh38: Ensembl release 89: ENSG00000275525, ENSG00000277398, ENSG00000104974, ENSG00000274935 - Ensembl, May 2017
2. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
3. "Entrez Gene: Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1".

Further reading

• Allen RL, Raine T, Haude A, Trowsdale J, Wilson MJ (November 2001). "Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures". Journal of Immunology. 167 (10): 5543–7. doi:10.4049/jimmunol.167.10.5543. PMID 11698424.
• Tedla N, Lee CW, Borges L, Geczy CL, Arm JP (February 2008). "Differential expression of leukocyte immunoglobulin-like receptors on cord-blood-derived human mast cell progenitors and mature mast cells". Journal of Leukocyte Biology. 83 (2): 334–43. doi:10.1189/jlb.0507314. PMID 17998301. S2CID 17379108.
• Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D, Beck S, Trowsdale J (April 2000). "Plasticity in the organization and sequences of human KIR/ILT gene families". Proceedings of the National Academy of Sciences of the United States of America. 97 (9): 4778–83. doi:10.1073/pnas.080588597. PMC 18309. PMID 10781084.
• Brown D, Trowsdale J, Allen R (September 2004). "The LILR family: modulators of innate and adaptive immune pathways in health and disease". Tissue Antigens. 64 (3): 215–25. doi:10.1111/j.0001-2815.2004.00290.x. PMID 15304001.
• Tedla N, An H, Borges L, Vollmer-Conna U, Bryant K, Geczy C, McNeil HP (April 2011). "Expression of activating and inhibitory leukocyte immunoglobulin-like receptors in rheumatoid synovium: correlations to disease activity". Tissue Antigens. 77 (4): 305–16. doi:10.1111/j.1399-0039.2011.01633.x. PMID 21388353.
• Pilsbury LE, Allen RL, Vordermeier M (2010). "Modulation of Toll-like receptor activity by leukocyte Ig-like receptors and their effects during bacterial infection". Mediators of Inflammation. 2010: 536478. doi:10.1155/2010/536478. PMC 2903975. PMID 20634939.
• Borges L, Hsu ML, Fanger N, Kubin M, Cosman D (December 1997). "A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules". Journal of Immunology. 159 (11): 5192–6. PMID 9548455.
• Ryu M, Chen Y, Qi J, Liu J, Fan Z, Nam G, Shi Y, Cheng H, Gao GF (April 2011). Kanellopoulos J (ed.). "LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence". PLOS ONE. 6 (4): e19245. doi:10.1371/journal.pone.0019245. PMC 3084784. PMID 21559424.
• Wang KS, Liu X, Aragam N, Mullersman JE, Jian X, Pan Y, Liu Y (February 2012). "Polymorphisms in ABLIM1 are associated with personality traits and alcohol dependence". Journal of Molecular Neuroscience. 46 (2): 265–71. doi:10.1007/s12031-011-9530-6. PMID 21547531. S2CID 6276103.